GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jiangsu Hengrui Pharmaceuticals Co Ltd (SHSE:600276) » Definitions » Beneish M-Score

Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Beneish M-Score : -3.17 (As of Apr. 27, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Jiangsu Hengrui Pharmaceuticals Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.17 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Jiangsu Hengrui Pharmaceuticals Co's Beneish M-Score or its related term are showing as below:

SHSE:600276' s Beneish M-Score Range Over the Past 10 Years
Min: -3.17   Med: -2.21   Max: -1.32
Current: -3.17

During the past 13 years, the highest Beneish M-Score of Jiangsu Hengrui Pharmaceuticals Co was -1.32. The lowest was -3.17. And the median was -2.21.


Jiangsu Hengrui Pharmaceuticals Co Beneish M-Score Historical Data

The historical data trend for Jiangsu Hengrui Pharmaceuticals Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jiangsu Hengrui Pharmaceuticals Co Beneish M-Score Chart

Jiangsu Hengrui Pharmaceuticals Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.71 -1.67 -2.44 -1.69 -2.87

Jiangsu Hengrui Pharmaceuticals Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.57 -2.04 -2.10 -2.87 -3.17

Competitive Comparison of Jiangsu Hengrui Pharmaceuticals Co's Beneish M-Score

For the Drug Manufacturers - General subindustry, Jiangsu Hengrui Pharmaceuticals Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jiangsu Hengrui Pharmaceuticals Co's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jiangsu Hengrui Pharmaceuticals Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Jiangsu Hengrui Pharmaceuticals Co's Beneish M-Score falls into.



Jiangsu Hengrui Pharmaceuticals Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Jiangsu Hengrui Pharmaceuticals Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.6776+0.528 * 0.989+0.404 * 1.1065+0.892 * 1.0956+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9246+4.679 * -0.091757-0.327 * 1.3152
=-3.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was ¥7,839 Mil.
Revenue was 5997.534 + 5806.153 + 5845.253 + 5676.059 = ¥23,325 Mil.
Gross Profit was 5054.685 + 4938.459 + 4957.071 + 4766.204 = ¥19,716 Mil.
Total Current Assets was ¥33,712 Mil.
Total Assets was ¥46,340 Mil.
Property, Plant and Equipment(Net PPE) was ¥6,574 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥9,113 Mil.
Total Current Liabilities was ¥3,698 Mil.
Long-Term Debt & Capital Lease Obligation was ¥78 Mil.
Net Income was 1368.929 + 828.657 + 1165.514 + 1069.158 = ¥4,432 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was 1254.599 + 3334.794 + 1433.523 + 2661.379 = ¥8,684 Mil.
Total Receivables was ¥10,559 Mil.
Revenue was 5492.32 + 5329.965 + 5717.264 + 4749.503 = ¥21,289 Mil.
Gross Profit was 4632.803 + 4512.074 + 4736.442 + 3916.872 = ¥17,798 Mil.
Total Current Assets was ¥30,650 Mil.
Total Assets was ¥42,294 Mil.
Property, Plant and Equipment(Net PPE) was ¥6,650 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥8,996 Mil.
Total Current Liabilities was ¥2,537 Mil.
Long-Term Debt & Capital Lease Obligation was ¥84 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(7839.496 / 23324.999) / (10559.337 / 21289.052)
=0.336098 / 0.495998
=0.6776

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(17798.191 / 21289.052) / (19716.419 / 23324.999)
=0.836026 / 0.845291
=0.989

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (33712.252 + 6573.892) / 46340.001) / (1 - (30650.444 + 6649.849) / 42293.83)
=0.13064 / 0.118068
=1.1065

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=23324.999 / 21289.052
=1.0956

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 6649.849)) / (0 / (0 + 6573.892))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(9113.14 / 23324.999) / (8996.341 / 21289.052)
=0.390703 / 0.422581
=0.9246

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((78.398 + 3698.072) / 46340.001) / ((83.914 + 2536.713) / 42293.83)
=0.081495 / 0.061962
=1.3152

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(4432.258 - 0 - 8684.295) / 46340.001
=-0.091757

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Jiangsu Hengrui Pharmaceuticals Co has a M-score of -3.17 suggests that the company is unlikely to be a manipulator.


Jiangsu Hengrui Pharmaceuticals Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Jiangsu Hengrui Pharmaceuticals Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Business Description

Traded in Other Exchanges
N/A
Address
No. 38, Huanghe Road, Economic, Economic and Technological Development Zone, Jiangsu Province, Lianyugang, CHN, 222047
Jiangsu Hengrui Pharmaceuticals Co Ltd is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs and anti-infection medications. It specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system.

Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Headlines

No Headlines